Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polatuzumab vedotin + venetoclax + ibrutinib + prednisone + obinutuzumab + lenalidomide
- Development stage
- Unknown
- Lead developer
- National Cancer Institute
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Oral, Intravenous
01
Overview
ViPOR-P is an experimental combination chemoimmunotherapy regimen being evaluated for the treatment of relapsed or refractory B-cell lymphomas. The regimen consists of six agents: polatuzumab vedotin (an anti-CD79b antibody-drug conjugate), venetoclax (a BCL-2 inhibitor), ibrutinib (a BTK inhibitor), prednisone (a corticosteroid), obinutuzumab (an anti-CD20 monoclonal antibody), and lenalidomide (an immunomodulatory imide drug). This multi-targeted approach is designed to simultaneously inhibit multiple survival pathways in malignant B cells, potentially overcoming resistance to standard therapies. The regimen is currently being investigated in a Phase 1 clinical trial sponsored by the National Cancer Institute (NCI) to determine its safety and efficacy in patients with aggressive and indolent B-cell lymphomas.
- Other names
- polatuzumab-National Cancer Institute (NCI)-B-cell lymphomaViPOR-P regimen
02
Targets
BCL-2 (BCL-2 family)CD20 (B-lymphocyte antigen CD20)CRBN (Cereblon)BTK (Bruton tyrosine kinase)B-cell antigen receptor complex-associated protein beta chainGR (Glucocorticoid receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on polatuzumab vedotin + venetoclax + ibrutinib + prednisone + obinutuzumab + lenalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polatuzumab vedotin + venetoclax + ibrutinib + prednisone + obinutuzumab + lenalidomide.